Edition:
United States

Innovate Biopharmaceuticals Inc (INNT.OQ)

INNT.OQ on NASDAQ Stock Exchange Capital Market

6.18USD
20 Jul 2018
Change (% chg)

$-0.38 (-5.79%)
Prev Close
$6.56
Open
$6.59
Day's High
$6.59
Day's Low
$6.06
Volume
84,528
Avg. Vol
93,221
52-wk High
$50.50
52-wk Low
$3.43

Chart for

About

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and... (more)

Overall

Beta: --
Market Cap(Mil.): $168.56
Shares Outstanding(Mil.): 25.70
Dividend: --
Yield (%): --

Financials

  INNT.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -7.26 -- --
ROI: -494.49 -3.67 13.17
ROE: -514.78 -5.61 15.10

BRIEF-Innovate Biopharmaceuticals Reports Q1 Loss Per Share Of $0.76

* AT MARCH 31, 2018, CO HELD $13.0 MILLION IN CASH AND CASH EQUIVALENTS Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Innovate Biopharma Files For Mixed Shelf Of Up To $175 Mln

* INNOVATE BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $175.0 MILLION - SEC FILING

Mar 15 2018

BRIEF-Innovate Appoints June Almenoff As COO, Chief Medical Officer

* INNOVATE BIOPHARMACEUTICALS APPOINTS JUNE ALMENOFF, M.D., PH.D. AS CHIEF OPERATING OFFICER AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

Mar 13 2018

Earnings vs. Estimates